Industrial Policy & Trade Monitor· 2662 actions· ✨ 89 recent

The Office of the United States Trade Representative released the 2026 Special 301 Report on 30 April 2026, designating Vietnam as a Priority Foreign Country (PFC) — the most severe category under Section 182 of the Trade Act of 1974 (19 U.S.C. § 2242). This is the first PFC designation since Ukraine held the status from 2013 through 2015, a gap of approximately 11 years. The PFC designation triggers a statutory 30-day window (expiring ~30 May 2026) within which USTR must decide whether to initiate a Section 301 investigation under 19 U.S.C. § 2412(b)(2)(A), which could lead to tariffs, withdrawal of trade benefits, or other Section 301 enforcement remedies against Vietnam. Separately, the EU was added to the Watch List for the first time, citing AI training-data, geographical-indications, and customs-enforcement concerns.

On 2 April 2026 President Trump issued a Presidential Proclamation under Section 232 of the Trade Expansion Act of 1962 ("Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients into the United States") imposing a 100% ad valorem tariff on imports of patented pharmaceutical products listed in the FDA Orange Book and Purple Book, together with the active pharmaceutical ingredients (APIs) and key starting materials used to make them. The base rate takes effect at 12:01 a.m. EDT on 31 July 2026 for the 17 manufacturers identified in Annex III, and on 29 September 2026 for all other companies. The proclamation adopts findings of the Section 232 investigation initiated by the Department of Commerce on 14 April 2025 into pharmaceuticals and APIs as a national- security supply-chain risk. The instrument is structured around a multi-tier rate ladder rather than a flat tariff: concessionary 15% rates for EU/Japan/South Korea/Switzerland/Liechtenstein under reciprocal-deal tracks, 10% for the UK with a pathway to 0% under the pending UK pharmaceutical agreement, a "+20%" surcharge for companies operating under a Commerce-approved onshoring plan (until 2 April 2030), and a 0% pathway for companies that combine an approved onshoring plan with an MFN-pricing agreement with HHS (until 20 January 2029). Generics, biosimilars and their ingredients, orphan drugs, nuclear medicines, plasma-derived therapies, fertility treatments, and cell/gene therapies are carved out.

President Trump signed a Presidential Proclamation on 20 February 2026 invoking Section 122 of the Trade Act of 1974 (19 U.S.C. § 2132) to impose a temporary 10% ad-valorem import surcharge on articles imported into the United States, effective 12:01 a.m. EST on 24 February 2026. The proclamation was issued within hours of the US Supreme Court's 20 February 2026 ruling in Learning Resources, Inc. v. Trump, which held that the International Emergency Economic Powers Act (IEEPA) does not authorize the president to set tariffs and vacated the IEEPA-based reciprocal-tariff regime previously in effect. The Section 122 surcharge is statutorily limited to 150 days (terminates 24 July 2026 absent Congressional extension) and the statute caps any such surcharge at 15% ad valorem. Goods qualifying as USMCA originating from Canada or Mexico are exempt; CAFTA-DR textile/apparel articles meeting specified rules of origin are exempt; and a substantial product-exception list excludes critical minerals, energy products, certain pharmaceuticals, electronics, vehicles, aerospace products, specified agricultural goods, and goods already subject to Section 232 duties (the Section 122 duty does not stack on Section 232).

On 12 February 2026, Ambassador Jamieson Greer of the Office of the United States Trade Representative oversaw the signing of the US-Taiwan Agreement on Reciprocal Trade (ART) in Washington, DC. The instrument was signed under the auspices of the American Institute in Taiwan (AIT) and the Taipei Economic and Cultural Representative Office in the United States (TECRO). Headline terms: (i) US IEEPA reciprocal-tariff rate on Taiwan reduced from 20% to 15% and Section 232 auto-parts/timber/lumber rate cut from 25% to 15%; (ii) Taiwan eliminates or reduces 99% of its tariff barriers on US goods, most immediately and the remainder phased over three years; (iii) Taiwan side commits ~USD 85bn in directed purchases through 2029 (USD 44.4bn LNG/crude, USD 15.2bn civil aircraft and engines, USD 25.2bn power equipment); (iv) sectoral chapters covering tariffs, non-tariff barriers, digital trade, economic security, and high-tech supply-chain resilience. Operationally linked to the 15 January 2026 AIT-TECRO Memorandum of Understanding on investment, under which Taiwan pledges USD 250bn in direct Taiwanese-enterprise investment in the US plus USD 250bn in Taiwan-government credit guarantees (USD 500bn total) to fund US-side industrial parks/clusters in advanced semiconductors, energy, and AI manufacturing. Entry into force is conditional on Taiwan's Legislative Yuan completing its review.

On 9 February 2026 USTR Ambassador Jamieson Greer and Bangladesh Adviser Sheikh Bashir Uddin signed the Agreement on Reciprocal Trade (ART) between the United States and Bangladesh in Washington DC — USTR's first ART signing in South Asia, preceding the US-India interim-trade-framework finalisation by three days. The deal locks the US reciprocal tariff on Bangladesh-originating goods at 19% (down from 35% under the April 2025 IEEPA regime) and establishes a zero-percent mechanism for products on the Annex III aligned- partner list (EO 14346, 5 September 2025). Bangladesh commits to significant preferential market access for US industrial and agricultural goods — including chemicals, machinery, motor vehicles, medical devices, ICT equipment, energy products, soy, dairy, beef, poultry, tree nuts, and fruit — and to eliminating specified non- tariff barriers including acceptance of US Federal motor-vehicle safety and emissions standards, FDA certificates, and prior marketing authorisations for medical devices and pharmaceuticals.

On 6 February 2026 Presidents Trump and Modi announced a framework for an Interim Trade Agreement that resets the bilateral tariff posture installed in 2025. Two operative instruments: (i) an executive order signed 6 February eliminating, effective 7 February 2026, the additional 25% IEEPA "Russian-oil" duty on Indian imports imposed by EO 14329 (27 August 2025), conditional on India's commitment to cease buying Russian crude and to expand defence cooperation; and (ii) reduction of the EO 14257 reciprocal-tariff rate on India from 25% to 18% on listed product categories (textiles and apparel, leather and footwear, plastics and rubber, organic chemicals, home décor, artisanal products, certain machinery), to take effect on finalisation of the Interim Agreement. India commits to eliminate or reduce tariffs on all US industrial goods and a wide range of agricultural products (DDGs, red sorghum, tree nuts, fresh and processed fruit, soybean oil, wine, spirits) and to purchase >USD 500bn of US energy, ICT, coal, aircraft and aircraft parts, and precious-metals products over five years. The framework also commits the parties to negotiating "robust, ambitious, and mutually beneficial digital trade rules" and to addressing non-tariff barriers in medical devices, ICT import licensing, and food/agricultural standards. US tariff reductions on Indian generic pharmaceuticals, gems, diamonds, aircraft parts, and certain automotive components are flagged as contingent on completion of the full Interim Agreement.

The Commonwealth of Pennsylvania, via Governor Josh Shapiro's office and the Department of Community & Economic Development, assembled a $100 million public incentive package — up to $50 million via the PA Edge Tax Credit Program, a $25 million PA SITES (Strategic Investments to Enhance Sites) grant, a $25 million Pennsylvania First grant, and up to $5 million via the Redevelopment Assistance Capital Program (RACP) for workforce development — to secure a $3.5 billion private investment from Eli Lilly and Company, the company's first manufacturing facility in Pennsylvania. The 925,000-square-foot facility will be built at the Fogelsville Corporate Center in Upper Macungie Township, Lehigh County, to produce next-generation weight-loss medicines, creating at least 850 new jobs over five years. It is the largest life-sciences investment in Pennsylvania history.

On 14 January 2026 President Trump issued a Presidential Proclamation under Section 232 of the Trade Expansion Act of 1962 titled "Adjusting Imports of Processed Critical Minerals and Their Derivative Products into the United States". Unlike the parallel 14 January 2026 semiconductor proclamation and the subsequent April 2026 pharmaceutical proclamation, the PCMDP proclamation does NOT immediately impose tariffs. Instead it directs the Secretary of Commerce and the U.S. Trade Representative to jointly negotiate bilateral and plurilateral supply agreements with trading partners, with an initial 180-day status report due 13 July 2026. The proclamation reserves residual authority to impose tariffs if negotiations fail or prove ineffective, and explicitly contemplates "price floors" on PCMDP imports as a negotiated instrument.

Section 851 of the FY 2026 National Defense Authorization Act (P.L. 119-60), signed December 18, 2025, prohibits US federal agencies from procuring biotechnology equipment or services from designated "biotechnology companies of concern" (BCCs), and bars federal contractors from using such equipment/services in work performed under federal contracts, grants, or loans. The final enacted text ties initial BCC designations to DoD's existing §1260H Chinese-military-company list (which currently includes BGI and MGI, but not WuXi AppTec or WuXi Biologics) and directs OMB to designate additional BCCs within one year of enactment; operational prohibitions activate 60-90 days after FAR revision, with a five-year grandfather period for pre-existing contracts — enforcement is expected to begin in 2027-28. The legislation is the successor to H.R.8333 (118th Congress, House-passed September 2024 but stalled in the Senate before adjournment) and represents the first enacted US federal-procurement biotech-supply-chain-resilience statute.

On 13 November 2025, the United States and the Republic of Korea released a Joint Fact Sheet reaffirming the July 2025 announcement of the Korea Strategic Trade and Investment Deal — the first standalone US-Korea trade-and-investment agreement since the 2012 KORUS FTA. USTR issued the implementing Federal Register notice (90 FR 55964, Notice 2025-21940) on 3 December 2025, effective 4 December 2025, with retroactive HTSUS application to 1 November 2025 for autos and auto parts and to 14 November 2025 for reciprocal-tariff goods, timber, lumber, derivatives, and certain aircraft and aircraft parts. On the US tariff side: (i) the country-specific IEEPA reciprocal tariff on Korean originating goods is set at the higher of the KORUS FTA / MFN rate or 15% (parallel to the Japan and EU framework deals); (ii) the Section 232 tariffs on autos, auto parts, timber, lumber and wood derivatives are reduced to 15% (no incremental duty when the pre-existing KORUS/MFN rate already meets or exceeds 15%); (iii) Korean exports of qualifying goods on the Potential Tariff Adjustments for Aligned Partners (PTAAP) list are exempt from reciprocal tariffs (covering generic pharmaceuticals and unavailable natural resources); (iv) Section 232 pharmaceuticals capped at 15%; semiconductors granted MFN-style "no less favourable" treatment in any future sectoral deal. On the investment side, Korea commits to a USD 350bn package: USD 150bn into US shipbuilding ("Approved Investments") plus USD 200bn into US strategic industries via a separate Strategic Investments MOU, with annual currency-funding cap of USD 20bn. Non-tariff commitments include streamlined US biotech approvals on the Korean side, US meat and cheese market access, fair treatment for US digital services, removal of Korea's 50,000-unit cap on US vehicles meeting FMVSS, and joint WTO support for the moratorium on customs duties on electronic transmissions.

On 5 February 2026, USTR Ambassador Jamieson Greer and Argentine Foreign Minister Pablo Quirno signed in Washington the United States-Argentina Agreement on Reciprocal Trade and Investment (ARTI), formalising the framework jointly announced on 13 November 2025. The agreement is the first standalone bilateral trade-and-investment instrument concluded by the second Trump administration and the first FTA-style agreement signed under the post-IEEPA reciprocal-tariff architecture (Executive Order 14257, "Liberation Day"). On the US side, the ARTI sets out three tariff schedules: (i) Schedule 2A suspends additional reciprocal tariffs under EO 14257 for specified Argentine-origin goods (covering "unavailable natural resources" and non-patented pharmaceutical inputs); (ii) Schedule 2B grants a zero additional reciprocal tariff for designated Argentine agricultural products under EO 14360; and (iii) caps additional ad-valorem duties on other goods at 10% above MFN rates, inclusive of IEEPA reciprocal tariffs. On the Argentine side, illustrative tariff-rate quotas include duty-free access for 80,000 MT of US beef in calendar year 2026, 1,000 MT for cheese, 870 MT for almonds, 40 MT in-shell + 40 MT shelled for pistachios, 80,000 litres for wine (<2 L bottles), and preferential treatment for 10,000 motor vehicles meeting defined technical parameters. Argentina additionally commits to broader preferential market access on medicines, chemicals, machinery, information-technology products, medical devices, and a wide range of agricultural goods, alongside IP-enforcement upgrades (counterfeit/pirated-goods enforcement, patentability criteria, patent-backlog reduction, geographical indications) and investment-facilitation commitments that align Argentina's regime with US-preferred standards on regulatory cooperation, labour and environment.

On 6 October 2025, the US Treasury's Office of Foreign Assets Control (OFAC) designated 8 Mexican individuals and 12 Mexico-based companies under Executive Order 14059 for supplying fentanyl precursor chemicals and laboratory equipment to the Sinaloa Cartel's "Los Chapitos" faction, led by fugitive brothers Archivaldo Ivan and Jesus Alfredo Guzman Salazar (sons of Joaquin "El Chapo" Guzman Loera). The network is centred on Sumilab, a chemical and lab-equipment supplier previously sanctioned by OFAC in May 2023, which restructured through affiliated pharmaceutical, laboratory, chemical, cleaning-supply and real-estate front companies to continue operating after the earlier designation. All property and interests in property of the designated persons within US jurisdiction or held by US persons are blocked, and US persons are generally prohibited from transacting with them.

President Trump signed Executive Order 14345 on 4 September 2025, implementing the July 2025 US-Japan trade agreement by setting a 15% baseline ad-valorem tariff on nearly all Japanese goods — raising any Column 1 (MFN) duty rate below 15% up to that floor, including on agricultural lines such as cereals, vegetables, and fruits and nuts. The modification applies retroactively to Japanese products entered for consumption on or after 12:01 a.m. EDT, 7 August 2025, and supersedes the higher 24% country-specific reciprocal rate Japan faced under the April 2025 "Liberation Day" schedule. Aerospace products are exempted entirely, autos/auto parts receive the same 15% treatment (down from a separate 25% Section 232 rate), and Japan committed to $550bn in US investment and $8bn/year in additional US agricultural purchases (rice, corn, soybeans, fertilizer, bioethanol) as consideration.

On 3 September 2025, the U.S. Treasury's Office of Foreign Assets Control (OFAC) designated Guangzhou Tengyue Chemical Co., Ltd., a China-based chemical manufacturer, along with two of its representatives, Huang Xiaojun and Huang Zhanpeng, pursuant to Executive Order 14059 for materially contributing to the international proliferation of illicit drugs. The company was found to have manufactured and sold synthetic opioids — including nitazenes — and analgesic cutting agents such as xylazine and medetomidine to U.S. buyers. The designation blocks all U.S.-person property and transactions involving the three designated persons and any entity 50%-or-more owned by them; the FBI simultaneously announced a related federal indictment against Guangzhou Tengyue, the two individuals, and roughly 22 other China-based individuals and businesses for conspiracy to commit drug trafficking.

On 13 August 2025 President Trump signed an Executive Order ("Ensuring American Pharmaceutical Supply Chain Resilience by Filling the Strategic Active Pharmaceutical Ingredients Reserve", Federal Register Doc. 2025-15823, published 19 August 2025) directing the HHS Assistant Secretary for Preparedness and Response (ASPR) to refill and operationalise the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR). Within 30 days, ASPR must compile an initial list of 26 essential drugs, account for available funding, and acquire and maintain a six-month supply of the corresponding APIs. Within 90 days, ASPR must deliver an expanded list of up to 86 essential medicines and medical countermeasures plus a plan to source those APIs from domestic manufacturers, and within 120 days (subject to appropriations) ready the existing SAPIR repository and submit a proposal and cost estimate for opening a second repository. The order prioritises domestically manufactured APIs in federal procurement and reserve build-out and directs interagency coordination across HHS/ASPR, FDA, DoD (Industrial Base Fund / Defense Production Act Title III), and the Department of Commerce.

Wisconsin Governor Tony Evers and the Wisconsin Economic Development Corporation (WEDC) announced on 5 August 2025 a package of up to $100 million in performance-based Enterprise Zone state tax credits to support Eli Lilly and Company's $4 billion expansion of its parenteral (injectable) drug manufacturing site in Bristol, Kenosha County. The credits are split between up to $18 million for job creation and up to $82 million for capital investment, contingent on Lilly creating at least 700 jobs and making at least $2.2 billion in qualifying capital investment, with the allocation period running through 2036.

On 27 July 2025, President Trump and European Commission President Ursula von der Leyen reached political agreement at Turnberry, Scotland, on a Framework Agreement on Reciprocal, Fair and Balanced Trade. The framework was formalised in a Joint Statement published on 21 August 2025 by the White House and DG TRADE. The deal establishes a 15% all-inclusive (MFN + Section 232) US tariff ceiling on the vast majority of EU originating goods — including autos, pharmaceuticals, semiconductors, lumber, and chemicals — replacing the threatened 20-30% reciprocal tariff trajectory under EO 14257 (April 2025). Steel and aluminium are excluded from the 15% ceiling and remain at the 50% Section 232 rate pending negotiation of a quota solution. In return, the EU commits to: (i) eliminate tariffs on all US industrial goods, (ii) preferential market access for a wide range of US agricultural and seafood products, (iii) suspension of its rebalancing countermeasures under Reg 2025/778 (suspension effective 7 August 2025), (iv) expected energy offtake of $750bn (LNG, oil, nuclear) through 2028, (v) at least $40bn in US AI chip purchases, and (vi) facilitation of $600bn in additional EU corporate investment into the US through 2028. Effective from 1 September 2025, the US applies MFN-only treatment (no 15% top-up) to: aircraft and parts, generic pharmaceuticals and ingredients, chemical precursors, cork, and certain unavailable natural resources. The framework is not legally binding but anchors the bilateral architecture; it is the largest-economy ART-programme deal alongside US-UK, US-Japan, US-Korea, US-Taiwan, and US-Indonesia.

President Trump signed Executive Order 14273, "Delivering Most- Favored-Nation Prescription Drug Pricing to American Patients", on 12 May 2025. The EO directs HHS, USTR, and Commerce to pursue mechanisms (negotiation targets, importation pathways, and trade-policy levers) to bring the prices Americans pay for innovative prescription drugs into alignment with the *lowest* prices paid by other comparably-developed nations — the "most-favored-nation" (MFN) benchmark. Unlike the Biden-era Inflation Reduction Act drug-price-negotiation provisions (which apply to a handful of Medicare Part D drugs), the EO applies pressure across the broader pharmaceutical pricing surface. As of April 2026, 17 major pharmaceutical manufacturers (incl. Eli Lilly, Pfizer, Bristol-Myers Squibb, AbbVie, Merck, AstraZeneca, Regeneron) have signed bilateral agreements bringing US drug prices toward the international- benchmark level for selected medications.

On 8 May 2025, President Trump and UK Prime Minister Starmer announced the General Terms of the US-UK Economic Prosperity Deal (EPD), the first bilateral framework arrangement of the second Trump administration and the template instrument for subsequent US bilateral framework deals (US-Japan, US-Indonesia, US-Argentina, US-Korea, US-EU). The framework was implemented on 23 June 2025 via Executive Order 14309 (Federal Register doc 2025-11473). Key US concessions: a 100,000-vehicle annual TRQ for UK autos at a 10% combined rate (7.5% + 2.5% MFN, vs. 27.5% Section 232 default); aerospace tariff reduction back to MFN rates; authority delegated to Commerce/USTR to establish UK-only TRQs for steel and aluminum (in lieu of the 50% Section 232 global rate). Key UK concessions: 13,000 mt duty-free beef quota (with 20% tariff removal on the existing 1,000 mt WTO quota); 1.4 billion litre duty-free ethanol quota; commitment to negotiate non-tariff barrier reductions and supply-chain security alignment. The 10% IEEPA "reciprocal" baseline tariff on most other UK goods is preserved by the EPD.

The U.S. Department of the Treasury's Office of Foreign Assets Control (OFAC) issued a final rule amending three sanctions programs. The rule adds a new general license at 31 CFR § 525.512 to the Burma Sanctions Regulations authorizing the provision of agricultural commodities, medicine, medical devices, replacement parts and components for medical devices, and software updates for medical devices to individuals whose property and interests in property are blocked. It also updates the authorities section of the Burma Sanctions Regulations to reflect recent legislation, replaces "the Office of Foreign Assets Control" / "the Director of the Office of Foreign Assets Control" with the acronym "OFAC" in three sections of the Sudan Stabilization Sanctions Regulations, and corrects a cross-reference in the Ukraine-/Russia- Related Sanctions Regulations. The rule is effective on publication.

The Bureau of Industry and Security (BIS) amended the Export Administration Regulations (EAR) on 8 February 2022 to add 33 persons — all based in China — to the Unverified List (UVL) under EAR §744.15(c), on the basis that BIS could not satisfactorily complete end-use checks for these entities for reasons outside US Government control. Placement on the UVL bars exporters from using any EAR license exception when shipping controlled items to listed parties and requires exporters to obtain a certified UVL Statement from the entity or secure a BIS export licence. Sectors represented include semiconductor manufacturing equipment, optoelectronics, UAVs, specialty chemicals, and biotechnology.

BIS amends the Export Administration Regulations (EAR) Commerce Control List to clarify the scope of ECCN 1C991 (vaccines, immunotoxins, and related medical products containing or derived from controlled biological agents) consistent with release and exclusion notes adopted at the June 2019 Australia Group (AG) Plenary Meeting. The rule adds clarifying language specifying which vaccines and medical products fall inside versus outside the ECCN 1C991 control perimeter, ensuring that routine vaccines produced by standard manufacturing methods are properly excluded. The changes align US controls with the Australia Group Common Control Lists without introducing new country-specific restrictions or license requirements.

The Bureau of Industry and Security (BIS) amended the Chemical Weapons Convention Regulations (CWCR, 15 CFR Part 710) and Export Administration Regulations (EAR, 15 CFR Parts 712 and 745) to implement two OPCW Conference of States Parties decisions (C-24/DEC.4 and C-24/DEC.5) from November 2019. The rule adds four chemical families — two families of alkyl phosphonamidic fluorides, O-alkyl phosphoramidofluoridates, and quaternary/bisquaternary carbamates — to CWC Schedule 1(A), effective immediately upon publication. The rule also clarifies the definition of "production" in 15 CFR § 710.1 to include intermediates, by-products, and waste products generated within a defined manufacturing sequence.

The Trade Expansion Act of 1962 (Pub. L. 87-794, 76 Stat. 872), signed into law by President Kennedy on 11 October 1962 and codified at 19 U.S.C. §§ 1801–1991, is the foundational US statute granting the executive branch broad authority to negotiate tariff reductions and, critically via Section 232 (19 U.S.C. § 1862), to adjust imports of any article found by the Secretary of Commerce to threaten to impair national security. Section 232 empowers the President — on receipt of a Commerce Department affirmative national-security finding — to impose tariffs, quantitative restrictions, or other import-adjustment measures without congressional approval or WTO-required safeguard procedures. From 1962 to the Trump Administration's 2018–2026 wave of Section 232 Proclamations, the authority was invoked primarily for petroleum and machine-tool imports; since 2018 it has become the legal vehicle for national-security tariffs on steel, aluminum, automobiles, copper, timber, critical minerals, semiconductors, and pharmaceuticals, with 19+ IPTM-filed implementing instruments citing Pub. L. 87-794 / 19 U.S.C. § 1862 as their statutory parent.

The Defense Production Act of 1950 (Pub. L. 81-774, 64 Stat. 798, codified at 50 U.S.C. §§4501–4568) is the foundational US statute governing wartime and emergency industrial mobilization. Signed by President Truman on 8 September 1950 during the Korean War, the Act empowers the President to compel industrial priority-rated ordering (Title I / DPAS), authorize direct investment in domestic production capacity for critical industries (Title III), and conduct investment security review (Title VII, precursor to CFIUS). Reauthorized approximately 50 times, most recently extended through September 2025 by Pub. L. 115-263 (2018) and further extended under NDAA FY2026; it has been invoked by every Administration since 1950 and has accelerated dramatically since 2020 to target critical-minerals processing, semiconductor manufacturing, battery supply chains, biopharmaceuticals, and energy infrastructure.